- Home
- MKL vs GMAB Comparison
MKL vs GMAB Comparison
Compare MKL & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKL | GMAB |
|---|---|---|
| Founded | 1930 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6B | 20.3B |
| IPO Year | 1999 | 2008 |
Fundamental Metrics
Financial Performance| Metric | MKL | GMAB |
|---|---|---|
| Price | $1,852.41 | $37.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $1,951.50 | $44.40 |
| AVG Volume (30 Days) | 71.4K | ★ 3.8M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 73.57 | N/A |
| Revenue | ★ $15,513,233,000.00 | N/A |
| Revenue This Year | N/A | $26.48 |
| Revenue Next Year | $0.35 | $17.83 |
| P/E Ratio | $24.80 | ★ $1.90 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1,704.17 | $23.62 |
| 52 Week High | $2,207.59 | $40.17 |
Technical Indicators
Market Signals| Indicator | MKL | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 68.23 | 57.08 |
| Support Level | $1,770.53 | $31.88 |
| Resistance Level | $1,862.84 | $40.17 |
| Average True Range (ATR) | 25.76 | 1.40 |
| MACD | 14.78 | -0.02 |
| Stochastic Oscillator | 93.88 | 47.68 |
Price Performance
Historical ComparisonAbout MKL Markel Group Inc.
Markel's primary business is property and casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.